Bevenopran

Add links
Source: Wikipedia, the free encyclopedia.
Bevenopran
Legal status
Legal status
  • Investigational
Identifiers
  • 5-[2-Methoxy-4-[[2-(oxan-4-yl)ethylamino]methyl]phenoxy]pyrazine-2-carboxamide
JSmol)
  • COC1=C(C=CC(=C1)CNCCC2CCOCC2)OC3=NC=C(N=C3)C(=O)N
  • InChI=1S/C20H26N4O4/c1-26-18-10-15(11-22-7-4-14-5-8-27-9-6-14)2-3-17(18)28-19-13-23-16(12-24-19)20(21)25/h2-3,10,12-14,22H,4-9,11H2,1H3,(H2,21,25)
  • Key:ZGCYVRNZWGUXNQ-UHFFFAOYSA-N

Bevenopran (

INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors and was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation.[1][2][3] It reached phase III clinical trials for this indication before being discontinued.[4][5]

See also

References

  1. S2CID 207475985
    .
  2. S2CID 34614812
    .
  3. ISBN 978-0-12-417151-0
    .
  4. ^ Combating Opioid-Induced Constipation: New and Emerging Therapies
  5. ^ Bevenopran



gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Bevenopran&oldid=1125428544"